Article

Advancing Genetic Tools in Streptococcus pneumoniae

Haley Echlin and Jason W. Rosch *

Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA; haley.echlin@stjude.org
* Correspondence: jason.rosch@stjude.org; Tel.: +1-901-595-3408

Received: 6 July 2020; Accepted: 15 August 2020; Published: 20 August 2020

Abstract: Streptococcus pneumoniae is the causative agent of a multitude of diseases, and further study into its pathogenies is vital. The pneumococcus is genetically malleable, and several tools are available to manipulate this pathogen. In this study, we attempted to utilize one such tool, the Sweet Janus cassette, to replace the capsule locus with other capsule loci in our strain background and found that the efficiency of allelic replacement was low and the number of revertant false-positive colonies was high. We determined that the capacity to recombine capsule varied by the initial isolated colony, suggesting that frequency of reversion is dependent on the bacterial clone. Alternative selection markers may further expand the application of Sweet Janus. We created novel cassettes that utilized chlorinated phenylalanine as an alternative counter-selection agent in conjunction with the Janus or Sweet Janus cassette, providing a new dual or triple selection marker. Moreover, we created cassettes that do not require engineered resistance in the background strain, including both single and dual selection markers. We were able to utilize all constructs in allelic replacement of the capsule loci. These novel constructs provide a new means for generating gene deletions in S. pneumoniae that expand experimental applications.

Keywords: markerless cassette; Streptococcus pneumoniae; allelic replacement

1. Introduction

Streptococcus pneumoniae is a major human pathogen with high rates of mortality and disease, including sinusitis and otitis media, pneumonia, bacteremia, and meningitis [1]. Although a current vaccine against a subset of serotypes demonstrates limited coverage while providing great protection against colonization and invasive disease, the ability of the pneumococcus to exchange capsule, the vaccine target, and to readily obtain antibiotic resistance determinants underscores the importance for further study of this organism [2–5]. The role of any particular gene in pathogenesis can be readily assessed via genetic manipulation of S. pneumoniae, which is highly transformable [6]. While there are several means of creating genetic deletions, most involve introduction of resistant cassettes as a selectable marker to identify recombinants. Imparting resistance can have drawbacks in multiple forms, including inability to assess drug resistance in mutants due to potential cross-resistance, reduced number of potential combination of gene deletions, potential stress caused by production of resistance marker, and compromising experimental results. To overcome many of these shortcomings, a markerless cassette known as Janus was generated [7]. This cassette yielded the opportunity to study many gene functions in previously unavailable situations through allelic replacement or deletion [8–10].

The Janus cassette is comprised of a kanamycin (kan) resistance marker and a counter-selection marker that confers dominant streptomycin-sensitivity (rpsL). Allelic replacement occurs through a two-step transformation process. In the first step, the Janus cassette replaces the gene of interest through homologous recombination in a streptomycin resistant strain background, with selection for kanamycin resistance. With proper integration of the Janus cassette, mutants would be kanamycin...
resistant and streptomycin sensitive. In the second step transformation, the cassette is replaced with an alternate allele. These mutants would be kanamycin sensitive but regain streptomycin resistance upon loss of \( rpsL \) in the Janus cassette, which confers streptomycin sensitivity. One drawback to Janus is that the streptomycin-sensitive \( rpsL \) marker in the cassette can be spontaneously mutated to that of streptomycin resistance, leading to a high number of false-positive transformants that require a secondary screen [7]. To overcome this, a modified version of the Janus cassette was generated, termed Sweet Janus. This cassette follows the same principal of Janus but includes a second counter-selection marker (\( sacB \)) that confers sucrose sensitivity. With the Sweet Janus cassette, allelic replacement still occurs through a two-step transformation process. The first step is the same as with the Janus cassette, but upon the second step, the mutants would regain both streptomycin resistance and the ability to grow on sucrose. With two counter-selection markers, the revertant frequency and, thereby, number of false-positive transformants is greatly reduced [11].

Development of Sweet Janus has afforded a tool for more efficient allelic replacement in \( S. \ pneumoniae \) and has expanded the ability to study the impact of genetic disruption/replacement [12–15]. However, in this study, we have identified potential pitfalls. Successful recombination in the second transformation step was not equal in all bacterial clones. We found high variability in positive allelic replacement and false-positive frequency based on initial clone selection. This suggests that, for experiments that require multiple allelic replacements into the same background, a primary screening of Sweet Janus mutants would streamline downstream cloning. Additionally, both Janus and Sweet Janus rely on introduction of streptomycin resistance in the strain background prior to the first step of transformation. Thus, the continued presence of streptomycin resistance even upon allelic replacement of the cassette may limit the use of the mutated strain based on the desired downstream applications. As a potential alternative, we have constructed multiple novel cassettes that follow a similar two-step transformation protocol but no longer require generation of a streptomycin resistant strain and instead utilize sensitivity to growth on chlorinated phenylalanine as a selection marker. Moreover, we have created other cassettes that incorporate a combination of counter-selection agents of streptomycin resistance, sucrose sensitivity, and chlorinated phenylalanine sensitivity. While the efficacy of these new constructs was similar to Sweet Janus, these new tools will provide additional flexibility and experimental options for investigations with \( S. \ pneumoniae \).

2. Materials and Methods

2.1. Growth Conditions

\( S. \ pneumoniae \) was inoculated from frozen stocks onto tryptic soy agar (Millipore Sigma, Billerica, MA, USA) plates supplemented with 3% sheep blood and 20 \( \mu \)g/mL neomycin and grown in 5% \( CO_2 \) at 37 °C overnight. Bacterial culture on plates were used to inoculate liquid semi-defined media \( C + Y \) [16]. Strains used in this study are listed in Table 1 and the respective strain resistance and sensitivity are listed in Table 2.

| Strain Description                  | Source       |
|-------------------------------------|--------------|
| SPNYL001 capsular locus replaced with Sweet Janus | Li, et al. [11] |
| TIGR4 capsular locus replaced with Sweet Janus | This study |
| TIGR4 capsular locus replaced with NewSweet Janus | This study |
| TIGR4 capsular locus replaced with Phun | This study |
| TIGR4 capsular locus replaced with PhunSweet | This study |
| TIGR4 capsular locus replaced with Phun | This study |

Table 1. Strains used in this study.
Table 1. Cont.

| Strain          | Description                                           | Source                    |
|-----------------|-------------------------------------------------------|---------------------------|
| D39             | D39 wild type, serotype 2                             | This study                |
| D39S            | D39 with K56T mutation in rpsL (Sp_0251)              | This study                |
| D39Δcps::SweetJanus | Capsule locus replaced with Sweet Janus             | This study                |
| D39Δcps::NewSweetJanus | Capsule locus replaced with NewSweet Janus       | This study                |
| D39Δcps::PhunJanus | Capsule locus replaced with Phun Janus               | This study                |
| D39Δcps::PhunSweet | Capsule locus replaced with PhunSweet               | This study                |
| D39Δcps::Phun   | Capsule locus replaced with Phun                      | This study                |
| ABCA38          | Serotype 22F                                          | CDC                       |
| CDC007          | Serotype 6B                                           | CDC                       |
| ABCA31          | Serotype 35B                                          | CDC                       |
| 45              | Serotype 45                                           | CDC                       |
| CDC001          | Serotype 9V                                           | CDC                       |
| CDC004          | Serotype 23F                                          | CDC                       |
| DAW4            | Serotype 11                                           | CDC                       |
| ABCA61          | Serotype 3                                            | CDC                       |
| CDC030          | Serotype 12F                                          | CDC                       |
| CDC048          | Serotype 18C                                          | CDC                       |
| CDC009          | Serotype 15C                                          | CDC                       |
| TIGR4ΔspxB::Erm | spxB (Sp_0730) replaced with Erm                     | Echlin, et al. [12]       |
| TIGR4ΔspxB::SweetJanus | spxB (Sp_0730) replaced with Sweet Janus       | This study                |
| TIGR4ΔspxB::SweetJanus | spxB (Spd_0636) replaced with Sweet Janus     | This study                |
| ABCA31ΔspxB::SweetJanus | spxB replaced with Sweet Janus                   | This study                |
| CDC001SΔspxB::SweetJanus | spxB replaced with Sweet Janus               | This study                |

Table 2. Strain resistance (R) and susceptibility (S) to selection agents: 800 μg/mL streptomycin (Strep), 400 μg/mL kanamycin (Kan), 10% sucrose (Suc), and 10 mM chlorinated-phenylalanine (Chl-Phe).

| Strain          | Strep | Kan | Suc | Chl-Phe |
|-----------------|-------|-----|-----|---------|
| SpnYL001        | S     | R   | S   | R       |
| TIGR4           | S     | S   | R   | R       |
| TIGR4S          | R     | R   | R   | R       |
| TIGR4Δcps::SweetJanus | S     | R   | S   | R       |
| TIGR4Δcps::NewSweetJanus | S     | R   | S   | R       |
| TIGR4Δcps::PhunJanus | S     | R   | R   | S       |
| TIGR4Δcps::PhunSweet | S     | R   | S   | S       |
| TIGR4Δcps::Phun  | S     | R   | R   | S       |
| D39             | S     | S   | R   | R       |
| D39S            | R     | S   | R   | R       |
| D39Δcps::SweetJanus | S     | R   | S   | R       |
| D39Δcps::NewSweetJanus | S     | R   | S   | R       |
| D39Δcps::PhunJanus | S     | R   | R   | S       |
| D39Δcps::PhunSweet | S     | R   | S   | S       |
| D39Δcps::Phun   | S     | R   | R   | S       |

2.2. Genomic DNA Extraction

Strains were grown in 10 mL C + Y to late logarithmic (OD620 ~0.8), and bacterial culture was pelleted at 6000×g, 10 min. For PCR (polymerase chain reaction) amplification and capsule swap experiments, genomic DNA (gDNA) was obtained using aqueous/organic extraction. Briefly, the bacterial pellet was subjected to lysis in 1 mL PBS plus 50 μL 10% SDS, 50 μL 10% DOC, and 10 μL of 10 mg/mL Proteinase K (Sigma, St. Louis, MO, USA), followed by incubation at 37 °C until clear. Lysates were mixed with 500 μL of phenol: chloroform: isoamyl alcohol (Sigma) and transferred to phase-lock
tubes (Quantabio, Beverly, MA, USA). Organic and aqueous phases were separated by centrifugation as per instructions. The aqueous phase was mixed with 500 µL chloroform: isooamyl alcohol in the phase-lock tube, separated again by centrifugation, and then transferred to 100% ethanol for DNA precipitation. Precipitated DNA was washed in 70% ethanol, dried at 65 °C, and rehydrated in water. For confirmation of mutations, genomic DNA was extracted from pneumococcal strains using a modified version of the Wizard DNA extraction kit (Promega, Madison, WI, USA). The bacterial pellet was subjected to lysis in 500 µL PBS plus 50 µL 10% SDS and 50 µL 10% DOC, followed by incubation at 37 °C until clear. RNA was removed by addition of 3 µL of 4 mg/mL RNaseA (Promega) and incubation at 37 °C for 15 min. The remainder of the extraction followed the protocol provided with the kit, starting with step 3.

2.3. PCR Amplification and Transformation

All mutations were generated through transformation of *S. pneumoniae* with PCR products created through splicing by overlap extension (SOE) PCR (Figure S1) [17]. All PCR products were amplified using exTaq polymerase (TAKARA, Mountain View, CA, USA) following the recommended guidelines. Primers used are listed in Table 3. Template, primers, and expected size of each PCR product are listed in Table 4. To transform *S. pneumoniae*, PCR fragments were introduced to TIGR4 or D39 grown to OD620 ~0.07 in C + Y, along with competence stimulating peptide 2 or 1, respectively [18]. Cells were incubated for 3 h at 37 °C, and mutants were selected on TSA agar plates containing 3% sheep blood and 20 µg/mL neomycin plus the selective agent (Table 5): 800 µg/mL streptomycin (Sigma), 400 µg/mL kanamycin (Fisher, Fair Lawn, NJ, USA), 10% sucrose (Sigma), or 7.5–15 mM chlorinated phenylalanine (Cayman # 26168, Ann Arbor, MI, USA) [11,19,20].

| Primer   | Sequence                                                                 |
|----------|--------------------------------------------------------------------------|
| HE01     | GCCGTAGTCATCTTTTCTTGCCATC                                               |
| HE02     | CTGAGTTAGTTTTTGTAGTGTCATTGTTTC                                           |
| HE03     | GAACAAATGACACCTAÇAAAACCTAACTCAAG                                        |
| HE04     | CTAATTGGAACCCGGCTAAAGTTAG                                                |
| HE05     | CTGTACCAAGTGTTATCATCACCC                                                 |
| HE06     | GATTTGCGCTATTTTGGAACCATGG                                                |
| HE07     | CATCTTCTCATTCTCCCCATATTGAC                                               |
| HE08     | ATGCAAGAAGATGCGACCAAGATGAC                                               |
| HE09     | ATAAAAAATCAAAGGATGCAGCATTCTAAA-ATATGATGATCCACTCAACACACAGAAGACATCCATGAG  |
| HE10     | TAAGGATGCAGCCTTGTTGATTATAATG                                              |
| HE11     | TTATGCTTTTGAGCCTTTAGTACCACTATG                                           |
| HE12     | CGTACTAAAGGCCAAGAAACGATAA-GAATGATGAGATCCCGTTCTTGAGCCCGCTTAC              |
| HE13     | TTATTTCAAGCTTTTGCCGAGACTTCTTGTG                                      |
| HE14     | ATGTCACCACTTGGAGAACAACATTAATGAGC                                        |
| HE15     | GTCCAGACACAAAAGCCCGAGACGATGATAC                                           |
| HE16     | GTATCTCCTGGGCTTTTGGCTTGGCTTGAC                                           |
| HE17     | TTATTTAAACGTCTCTGAGAAGGCGGAC                                              |
| HE18     | GTGAGGCGAGAACGTTGGTACATGATG                                              |
| HE19     | CGCTTTTAAATGCTCTTCAATGCGATTTGTCATTATTTATCGGCTTCTCTTCCTCCTTACTAG          |
| HE20     | GATGTCGCTTCTGCTGAGGACTTTAGAAATAAAA-AAAAGCGAGACCGAGGCGGCGGCG              |
| HE21     | GATGTCGCTTCTGCTGAGGACTTTAGAAATAAAA-AAAAGCGAGACCGAGGCGGCGGCG              |
| HE22     | CCATTAAAATCAAAGGCTGCTGCTTCCTTAATGATACTGGAGAGGCGGCGGAC                      |
| HE23     | CTAAAACAACTTCCAGCTAAAAT                                              |
| HE24     | ATTTATCGAGATGAGTATGTTGTTTAGGAGGCCGCGACTGCTAGTTT                            |
| HE25     | TCAAACGAGATGCGGATCCTTTAAA-ATGATGACTACCTTTCAATTTTTTTATATCCTGAG             |
| HE26     | ACTAAACGTCAGAAGAGATAA-TTCCCTCCTGGAAGAAATCAAATAATGACATTTGTG                |
| HE27     | CCATAGTCACTATACTACCGAGAAATTTCTG                                        |

Table 3. Primers used in this study. Point mutations are underlined.
Table 4. PCR (polymerase chain reaction) setup for cassette. Words in parentheses indicate overhang homology.

| PCR | Product | F Primer | R Primer | gDNA Template | Size |
|-----|---------|----------|----------|---------------|------|
| A   | RpsL_K56T Up | HE01     | HE02     | TIGR4         | 1149 |
| B   | RpsL_K56T Down | HE03     | HE04     | TIGR4         | 1015 |
| C   | DexB-SweetJanus-AliA | HE06     | HE07     | SpnYL001      | 6180 |
| D   | DexB (SacB)  | HE08     | HE09     | TIGR4         | 1608 |
| E   | SacB-Kan-RpsL | HE10     | HE11     | SpnYL001      | 2807 |
| F   | AliA (RpsL) | HE12     | HE13     | TIGR4         | 2135 |
| G   | PheS A315G Up | HE14     | HE15     | TIGR4         | 958  |
| H   | PheS A315G Down | HE16     | HE17     | TIGR4         | 120  |
| I   | DexB + Prom (PheS) | HE06     | HE19     | SpnYL001      | 1622 |
| J   | Kan-RpsL-AliA(PheS) | HE20     | HE07     | SpnYL001      | 3135 |
| K   | DexB-PheS A315G | HE06     | HE17     | TIGR4Δcps::PhunJanus | 2669 |
| L   | SacB-Kan-RpsL-AliA (PheS) | HE21   | HE07     | SpnYL001      | 4638 |
| M   | DexB-PheS A315G (SacB) | HE06     | HE22     | TIGR4Δcps::PhunJanus | 2669 |
| N   | SacB-Kan | HE10     | HE23     | SpnYL001      | 2350 |
| O   | AliA  | HE24     | HE07     | SpnYL001      | 1819 |
| P   | SJ Kan | HE20     | HE23     | SpnYL001      | 847  |

Table 5. Selective agents used in TSA (tryptic soy agar) plates when replacing the markerless cassette in step two transformation.

| Markerless Cassette | Counter-Selection Agents |
|---------------------|--------------------------|
| Sweet Janus         | 800 µg/mL Streptomycin + 10% Sucrose |
| NewSweet Janus      | 800 µg/mL Streptomycin + 10% Sucrose |
| Phun Janus          | 800 µg/mL Streptomycin + 7.5–15 mM Chlorinated-Phenylalanine |
| PhunSweet Janus     | 800 µg/mL Streptomycin + 10% Sucrose + 7.5–15 mM Chlorinated-Phenylalanine |
| PhunSweet           | 10% Sucrose + 7.5–15 mM Chlorinated-Phenylalanine |
| Phun                | 7.5–15 mM Chlorinated-Phenylalanine |

2.4. Generation of Streptomycin Resistant Strains

In this study, we aimed to delete the capsule locus with the Sweet Janus cassette, followed by allelic replacement with other capsule loci. Because the selection for allelic replacement requires the background strain to have streptomycin resistance, we first introduced this resistance to our TIGR4 and D39 strains. While there are multiple means of conferring streptomycin resistance, we mutated the gene encoding the 30 s ribosomal subunit S12, rpsL (Sp_0271; Spd_0251) via point mutation at nucleotide 167 (AAA → ACA), resulting in amino acid change K56T. We followed this strategy because it affords a known source of resistance, limiting the potential secondary mutations arising from spontaneous selection, and because it yields high levels of resistance [19]. The point mutation in rpsL was generated through SOE PCR using two fragments amplified from TIGR4 genomic DNA (Figure S1A). The upstream fragment (PCR A) consisted of the region about 1 kb upstream to 15 bp downstream of the point mutation and was amplified using primers HE01/HE02. The downstream fragment (PCR B) consisted of the region 15 bp upstream to about 1 kb downstream of the point mutation and was amplified using primers HE03/HE04. To generate the point mutation, HE02 and HE03 were designed so that the middle nucleotide of the primer was mutated. The mutated SOE PCR (PCR 1) was amplified using PCR A and B as templates and primers HE01/HE04 and was introduced...
into TIGR4 and D39 via transformation with selection of 800 µg/mL streptomycin—generating TIGR4S and D39S. Presence of the point mutation was confirmed in the SOE PCR and in the amplified gene from the chromosome of mutated strains via sequencing with primer HE05. No other mutations were observed in rpsL.

2.5. Replacement of Capsule Locus with Sweet Janus and NewSweet Janus Cassette

After confirming that TIGR4S obtained resistance to streptomycin, we replaced the TIGR4 capsule locus with Sweet Janus as described previously to create strain TIGR4S ∆cps::SweetJanus [11]. Briefly, we amplified the region from dexB (Sp_0342) through aliA (Sp_0366) from SpnYL001 (generously provided by Yuan Li from the Harvard School of Public Health, Cambridge, MA, USA), which incorporates the Sweet Janus replacement of the capsule locus (Figure S1B). This DexB-SweetJanus-AliA fragment (PCR C) was amplified using primers HE06/HE07, which have the same sequence as the primer pair (YL229/YL236) used to generate the allelic replacement previously [11]. This fragment includes genes that confer sucrose sensitivity (sacB), kanamycin resistance (kan), and streptomycin sensitivity (rpsL). The fragment was introduced into TIGR4S and mutants were selected with 400 µg/mL kanamycin. We isolated colonies that had no resistance to the counterselection agents, 800 µg/mL streptomycin plus 10% sucrose. If colonies did have resistance, they were considered to not be mutants. Mutation was confirmed by loss of capsule via agglutination using latex beads bound to antisera against type 4 capsule (Statens). D39S∆cps::SweetJanus was generated in a similar manner by transformation of D39S with PCR C.

To extend homology available for recombination, we created the modified “New” Sweet Janus cassette by splicing together three fragments using SOE PCR (Figure S1C). The first fragment (PCR D) was the entire dexB gene with an overhang sequence complementary to sacB plus the promoter region upstream of sacB from Sweet Janus cassette. This fragment was amplified from TIGR4 gDNA using primers HE08/HE09. The second fragment (PCR E) was comprised of the promoter region upstream of sacB, sacB, kan, and rpsL and was amplified from SpnYL001 gDNA using primers HE10/HE11 based on the Sweet Janus sequence (Accession# KJ845726). The third fragment (PCR F) was the entire aliA gene with an overhang sequence complementary to rpsL and was amplified from TIGR4 using HE12/HE13. Amplification using these primers only amplified aliA plus probable native promoter and excludes the upstream region included in the original DexB-SweetJanus-AliA, as this region has homology to D39, but not to TIGR4 (Figure S2). The SOE PCR (PCR 2) was amplified using PCR D, E, and F as templates and primer pair HE08/HE13. TIGR4S∆cps::NewSweetJanus was generated by transformation of TIGR4S with PCR 2, with selection of 400 µg/mL kanamycin. Mutants were confirmed to be unencapsulated via latex agglutination using latex beads bound to antisera against type 4 capsule (Statens). D39S∆cps::NewSweetJanus was generated in a similar manner by transformation of D39S with PCR C.

2.6. Allelic Replacement Efficacy

To determine the efficacy of allelic replacement in SpnYL001, TIGR4SΔcps::SweetJanus, and TIGR4SΔcps::NewSweetJanus, we determined the number of isolated colonies that recombined a type 2 capsule (true-positive) and the number of colonies that failed to recombine (false-positive) upon transformation with 4 µg of D39 gDNA. A colony was deemed to be true-positive if it was smooth (mucoid and opaque), while a colony was deemed to be false-positive if it was rough (non-mucoid and dull) and resembled the pre-transformed unencapsulated strain. A subset of true-positive and false-positive colonies was confirmed by latex agglutination for each transformation. We followed the same guidelines to test for variability in transformation efficacy among isolated colonies of TIGR4SΔcps::NewSweetJanus. The isolated colonies of TIGR4SΔcps::NewSweetJanus were obtained by selecting eight colonies from the transformation generating TIGR4S by introduction of the mutated rpsL (PCR 1) into TIGR4, followed by selection of two isolated colonies from each transformation generating TIGR4SΔcps::NewSweetJanus by introduction of PCR 2 into the eight
TIGR4S colonies. Similarly, to determine the efficacy of allelic replacement of specific capsule loci, we transformed TIGR4SΔcps::NewSweetJanus or D39SΔcps::NewSweetJanus via introduction of 4 µg of gDNA extracted from CDC isolates of different serotypes. We determined the number of isolated colonies that recombined the capsule loci (true-positive) and the number of colonies that failed to recombine (false-positive). Colonies that were smooth (mucoid and opaque) were deemed true-positive, and colonies that were rough (non-mucoid and dull) were deemed false-positive, with a subset confirmed by latex agglutination.

2.7. Allelic Replacement Efficacy of spxB

To determine if the observed variances of transformation efficacy occurs upon allelic replacement of other loci other than capsule, we performed a two-step transformation to replace spxB (Sp_0730) in TIGR4S, D39S, and in two clinical backgrounds—ABCA31S and CDC001S. To utilize Sweet Janus, streptomycin resistance was conferred first, as described above—by transformation of TIGR4, D39, ABCA31, and CDC001 with PCR 1 and selection of mutants on 800 µg/mL streptomycin—Generating TIGR4S, D39S, ABCA31S, and CDC001S. Two colonies from each transformation were selected for allelic replacement of spxB. In the first step transformation, spxB was replaced by Sweet Janus using SOE PCR. The upstream fragment (996 bp upstream of the start codon) was amplified using HE25/26 and the downstream fragment (962 bp downstream from the stop codon) was amplified using HE27/HE28, both from TIGR4 gDNA. Sweet Janus was amplified using HE10/HE11 from SpnYL001 gDNA. The SOE PCR was amplified using the upstream, downstream, and Sweet Janus fragments as template and primer pair HE25/HE28. The spxB::SweetJanus SOE PCR was introduced into the two colonies of TIGR4S, D39S, ABCA31S, and CDC001S and mutants were selected with 400 µg/mL kanamycin. Four colonies of ΔspxB::SweetJanus from each transformation were selected for the second step transformation (except for ABCA31S, where one and seven colonies were selected from the two ABCA31S colonies). For the second step transformation, Sweet Janus was replaced with a cassette conferring erythromycin resistance (Erm) by amplification of ΔspxB::Erm PCR from TIGR4ΔspxB::Erm using HE25/HE28. This PCR was introduced into the eight isolated colonies of TIGR4SΔspxB::SweetJanus, D39SΔspxB::SweetJanus, ABCA31SΔspxB::SweetJanus, and CDC001SΔspxB::SweetJanus, and transformants were selected on plates containing either 800 µg/mL streptomycin plus 10% sucrose or 1 µg/mL erythromycin. Colonies that grew on erythromycin were considered to be true-positive as Sweet Janus was replaced with Erm. Colonies that grew on streptomycin plus sucrose consisted of both true-positive (loss of Sweet Janus) and false-positive (loss of streptomycin sensitivity) colonies. The number of false-positive colonies was calculated by subtracting the number of true-positive colonies from the total number of transformants (those that grew on streptomycin plus sucrose).

2.8. Construction of Novel Markerless Cassettes for Allelic Replacement of Capsule Locus

To provide alternative markerless cassettes based on chlorinated phenylalanine sensitivity, we first generated a mutated form of pheS (Sp_0579 and Spd_0504), which encodes the α unit of the phenylalanyl-tRNA synthetase. A point mutation in pheS leading to amino acid change A315G allows for integration of chlorinated phenylalanine into proteins. With recombination of the mutated pheS, the pneumococcus will struggle to grow on media containing chlorinated phenylalanine as seen in other streptococci and as predicted previously [20]. To mutate pheS to generate amino acid change A315G (Figure S1D), two PCR fragments were amplified from TIGR4 gDNA. The upstream fragment (PCR G) consisted of the region from the start codon of pheS to 15 bp downstream of the point mutation (C to G at nucleotide 944) and was amplified using primers HE14/HE15. The downstream fragment (PCR H) consisted of the region 15 bp upstream of the point mutation to the stop codon of pheS and was amplified using primers HE14/HE15. To generate the point mutation, HE15 and HE16 were designed so that the middle nucleotide of the primer was mutated. The SOE PCR (PCR 3) with the point mutation was amplified using PCR G and H and primers HE14/HE15. Proper mutation of pheS was confirmed via sequencing with primer HE18.
The mutated pheS (PCR 3; pheS A315G) was incorporated into four novel cassettes: Phun Janus (pheS A315G, rpsL, kan), PhunSweet Janus (pheS A315G, sacB, rpsL, kan), PhunSweet (pheS A315G, sacB, kan), and Phun (pheS A315G, kan). As the novel cassettes were to be utilized for allelic replacement of the capsule locus, we generated Phun Janus, PhunSweet Janus, PhunSweet, and Phun by splicing the cassettes with DexB and AliA, the flanking genes of the capsule locus, via SOE PCR. Similar to Sweet Janus, Phun Janus relies on the counterselection of streptomycin sensitivity through rpsL, making it a necessity to first confer streptomycin resistance in the strain background. In contrast, PhunSweet and Phun do not contain rpsL and, thus, may be utilized in the native strain background. PhunSweet Janus has three possible counter-selection agents. In this study, a triple selection was utilized, requiring a strain background with streptomycin resistance. However, it may be possible to utilize only the chlorinated phenylalanine and the sucrose sensitivities of this cassette for counter-selection, allowing for use of this cassette in streptomycin sensitive strains.

For Phun Janus (Figure S1E), the upstream fragment (PCR I) included dexB plus the promoter region upstream of sacB from the Sweet Janus cassette, with an overhang complementary to the 5′ end pheS. The downstream fragment (PCR J) consisted of kan, rpsL, and aliA from Sweet Janus, with an overhang complementary to the 3′ end of pheS. Both fragments were amplified from SpnYL001 gDNA using primers HE06/HE19 (upstream fragment) and primers HE20/HE07 (downstream fragment). The SOE PCR (PCR 4) was amplified using PCR I, PCR J, and pheS A315G (PCR 3) with primers HE06/HE07 and was introduced into TIGR4S and D39S to generate TIGR4SΔcpc::PhunJanus and D39SΔcpc::PhunJanus. PhunSweet Janus (Figure S1F) is similar to Phun Janus, but with the insertion of sacB between pheS A315G and kan, and was generated by SOE PCR (PCR 5) of two fragments with primers HE06/HE07. The upstream fragment (PCR K) included dexB plus pheS A315G with promoter and was amplified from TIGR4SΔcpc::PhunJanus using primers HE06/HE17. The downstream fragment (PCR L) was comprised of sacB plus the promoter region upstream of sacB, kan, and rpsL from the Sweet Janus cassette, with an overhang complementary to the 3′ end of pheS. This fragment was amplified from SpnYL001 using primers HE21/HE07. TIGR4S and D39S were transformed with PCR 5 to generate TIGR4SΔcpc::PhunSweetJanus and D39SΔcpc::PhunSweetJanus. PhunSweet (Figure S1G) was generated through SOE PCR (PCR 6) of three fragments with primers HE06/HE07. The upstream fragment (PCR M) consisted of dexB plus pheS A315G with promoter, with an overhang complementary to sacB plus promoter. This fragment was amplified from TIGR4SΔcpc::PhunJanus using primers HE06/HE22. The middle fragment (PCR N) was comprised of sacB plus the promoter region upstream of sacB and kan and was amplified from SpnYL001 using primers HE10/HE23. The downstream fragment (PCR O) included the segment of aliA plus the sequence with D39 homology upstream of aliA, with an overhang complementary to the 3′ end of kan, and was amplified from SpnYL001 using primers HE24/HE07. PCR 6 was introduced into TIGR4 and D39 to generate TIGR4Δcpc::PhunSweet and D39Δcpc::PhunSweet. Phun (Figure S1H) consisted of pheS A315G and kan and was generated through SOE PCR (PCR 7) of three fragments with primers HE06/HE07. The upstream (PCR K) and downstream fragments (PCR O) have been described above. The middle fragment (PCR P) included kan with an overhang complementary to the 3′ end of pheS A315G and was amplified from SpnYL001 with primers HE20/HE23. TIGR4 and D39 were transformed with PCR 7 to generate TIGR4Δcpc::Phun and D39Δcpc::Phun. All mutants were confirmed to be unencapsulated and sensitive to counter-selection agents (Table 5). Any colony that was not sensitive to the counter-selection agents was not considered to be a mutant. One colony for each mutation was selected to determine allelic replacement efficacy via transformation with 4 μg of D39 gDNA and plating on the appropriate counter-selection agents as described above. The sequence of each cassette is available through NCBI—Phun Janus (#MT684775), PhunSweet Janus (#MT684776), PhunSweet (#MT684774), and Phun (#MT684777).
3. Results

3.1. Variances in Frequency of False-Positive Transformant Colonies

With its multiple potential applications, we sought to exploit the Sweet Janus system to create capsule swapped variants in our background strain [11]. To maintain an isogenic cell line, we utilized this system to generate an unencapsulated form of our TIGR4 through allelic replacement of the capsule locus with Sweet Janus. Since the Sweet Janus cassette relies upon streptomycin resistance in the background strain, we first generated a streptomycin resistant variant of TIGR4. To reduce the chance of obtaining secondary mutations that could arise from spontaneous mutation, we conferred streptomycin resistance by transformation of TIGR4 with a mutated \( rpsL \), which encodes ribosomal protein S12. The single substitution mutation of a lysine to threonine at position 56 (K56T) in \( rpsL \) confers a high level of streptomycin resistance [21]. We next replaced the capsule locus by transformation of TIGR4S with an amplicon of the entire Sweet Janus locus plus the homologous flanking regions, DexB and AliA, from strain SpnYL001, generously provided by Yuan Li from the Harvard School of Public Health. We had no difficulty obtaining correct transformants for either TIGR4S or for TIGR4S\( \Delta \)cps::SweetJanus. However, after several attempts, we could not obtain a capsule-swapped variant of type4 and a limited number of colonies that recombined type2 capsule despite having hundreds of transformant colonies. To confirm the counter-selection agents were accurate, we concurrently transformed SpnYL001 and TIGR4S\( \Delta \)cps::SweetJanus—both of which replaced the capsule locus with the same cassette—with D39 genomic DNA. As observed previously [11], SpnYL001 readily picked up the type2 capsule, with a low number of false-positives (Figure 1). In contrast, we obtained only seven positive colonies in our TIGR4S::SweetJanus strain but over 500 false-positives, which had the correct growth on the counter-selection agents but did not recombine the type 2 capsule locus. One possible explanation for the low number of true-positives—those colonies that underwent allelic replacement—could be an issue of reduced homology. DexB-SweetJanus-AliA was originally generated by introduction of \( sacB \) into DexB-Janus-AliA [8,11]. However, these cassettes were generated from the capsule locus of D39 and included regions of chromosome upstream of AliA that are not shared by TIGR4 (Figure S2). To determine if insufficient homology could explain the reduced ability of our TIGR4S\( \Delta \)cps::SweetJanus to recombine the capsule locus, we created a modified DexB-SweetJanus-AliA cassette where Sweet Janus was flanked by the entirety of DexB and AliA from TIGR4—named DexB-NewSweetJanus-AliA. However, transformation of TIGR4S\( \Delta \)cps::NewSweetJanus with D39 genomic DNA still had a low number of true-positives amid a high number of false-positive colonies (Figure 1).

3.2. Potential Reversion Necessitates Initial Screening for Mass Application

Since extended homology did not improve the frequency of allelic replacement, we next considered other aspects of this system. Sweet Janus was originally created to enhance counter-selection as streptomycin selection in Janus alone was not stringent enough to reduce the number of potential false-positives colonies. With the addition of \( sacB \) in Sweet Janus, the frequency of obtaining dual reversion was \( 10^4 \)-fold lower than the frequency of \( rpsL \) reversion alone [11]. Loss of streptomycin sensitivity can occur through spontaneous mutation in \( rpsL \) or through recombination with the resistant variant of \( rpsL \) present in the TIGR4 genome, with the latter likely occurring more frequently [7]. Inactivation of \( sacB \) can occur through spontaneous mutation, requiring as little as a single point mutation of C to T at position 1078 [11,22]. It is possible that, the pneumococcus could gain reversion against either \( sacB \), \( rpsL \), or both counter-selection agents. This reversion could occur during the first step (generation of TIGR4S\( \Delta \)cps::SweetJanus) or second step (allelic replacement) transformations. A reversion occurring during the first step transformation would become quickly apparent as, upon the second step transformation, a lawn of growth would be present, and isolated colonies would be absent. We observed isolated colonies upon the second step transformation, so it is unlikely reversion occurred during the first step. Indeed, we confirmed that TIGR4S\( \Delta \)cps::SweetJanus and TIGR4S\( \Delta \)cps::NewSweetJanus had no growth on the counter-selection agents (streptomycin plus
sucre). If reversion occurs during the second step transformation, then identification of true-positive colonies amongst false-positive colonies becomes more difficult, and further screening is required. It is possible that there is an inherent reason why a particular bacterial clone would be more likely to revert than another parallel clone.

![Graph showing the number of positive colonies](image)

**Figure 1.** Low efficiency was observed for allelic replacement of Sweet Janus in TIGR4S. SpnYL001, TIGR4SΔcps::SweetJanus, and TIGR4SΔcps::NewSweetJanus were transformed with D39 genomic DNA. The number of true-positive colonies (red bars, number above column) and the number of false-positive colonies (black bars) were determined per mL of transformation. Dashed line represents upper limit of detection.

To test if variance of background resistance depended on the particular bacterial clone, we repeated the transformation steps to generate isolated colonies of TIGR4SΔcps::NewSweetJanus. Since TIGR4 undergoes two transformation steps to generate TIGR4SΔcps::NewSweetJanus, it is possible that variances can occur at each step. To account for this, we isolated eight colonies after transforming rpsL K56T to generate TIGR4S, followed by isolation of two colonies of each of these eight TIGR4S colonies after transformation with the NewSweet Janus cassette. All colonies were confirmed to have no background resistance to the counter-selection agents (streptomycin plus sucrose) prior to allelic replacement transformation. Upon transformation with D39 genomic DNA, we observed variances in the number of true-positive (capsule positive) and false-positives (capsule negative) (Figure 2). Some clones (#7 and 8) had an innumerable amount of false-positive colonies with no true-positive colonies. Other clones (#1-1 and 4-1) had a few true-positive colonies, while having high levels of false-positive colonies. Two clones (#2-2 and 5-2) had several true-positive colonies despite high levels of false-positive colonies. One clone (#6-1) stood out in that it had a high number of true-positive colonies but a relatively low number of false-positive colonies. This result suggests that the frequency of reversion in pneumococcus is dependent on the particular bacterial clone. If a one-time allelic replacement is required, then screening the colonies from the second step transformation for loss of kanamycin resistance is a feasible solution to this problem. However, if multiple allelic replacements into the same background is required (e.g., capsule swapping several capsule types into the same genetic background), then screening hundreds of colonies from each of the transformations becomes unreasonable and time-consuming. Thus, if numerous allelic replacements are required, an initial screen to obtain a clone that has an increased true-positive/false-positive ratio (Table 6) is warranted.
TIGR4 PhunSweet Suc, Chl-Phe15mM 0.136
TIGR4 PhunSweet Suc, Chl-Phe10mM 0.13
TIGR4 PhunSweet Suc, Chl-Phe7.5mM 0.13

Figure 2. Efficiency of allelic replacement of NewSweet Janus in TIGR4S varied by isolated colony. Eight isolated colonies were selected from the transformation generating TIGR4S, followed by selection of two isolated colonies from each transformation generating TIGR4S::NewSweetJanus from the eight TIGR4S colonies. The colony numbers are listed as first transformation-second transformation. For example, “1-1” represents the first TIGR4S::NewSweetJanus colony in TIGR4S clone #1 and “2-1” represents the first TIGR4S::NewSweetJanus colony in TIGR4S clone #2. The sixteen colonies of TIGR4S::NewSweetJanus were transformed with D39 genomic DNA. The number of true-positive colonies (red bars, number above column) and the number of false-positive colonies (black bars) were determined per mL of transformation. Dashed line represents upper limit of detection.

To confirm that this initial selection yields a clone that is more efficient at recombining the desired allelic replacement (in this study-capsule), we utilized the TIGR4S::NewSweetJanus clone that had the highest true-positive/false-positive ratio (#6-1) to create capsule swap variants. While the original Sweet Janus and NewSweet Janus capsule deletion clones in our TIGR4 were ineffective at recombining capsule (Figure 1), TIGR4S::NewSweetJanus clone #6-1 had a high efficiency at recombining capsule, with correct allelic replacement occurring for seven of 13 capsule types on the first transformation attempt and 3 more on the second transformation attempt (Figure 3a, Table 7). To further confirm that vetting the transformation strain streamlines further allelic replacement, we identified a clone of D39S::NewSweetJanus that had a high true-positive/false-positive ratio and subjected it to transformation with genomic DNA from 13 different serotypes, with correct allelic replacement occurring for 11 of 13 capsule types (Figure 3b).

Figure 3. Identification of clones with high efficiency of allelic replacement streamlined multitude of capsule swaps. (a) TIGR4S::NewSweetJanus and (b) D39S::NewSweetJanus were transformed with genomic DNA from strains of different serotypes (below column). The number of true-positive colonies (red bars, number above column) and the number of false-positive colonies (black bars) were determined per mL of transformation. Dashed line represents upper limit of detection.
To confirm that the observed variances in transformation efficacy was not solely due to the large recombination event required for allelic replacement of the capsule locus, we determined the transformation efficacy of allelic replacement of spxB (Sp_0730) in TIGR4S, D39S, as well as, in two clinical backgrounds—ABCA31S and CDC001S. While the total number of true-positive colonies was dramatically increased compared to those of allelic replacement of the capsule locus, we still observed variances in the transformation efficacy depending on the initial clone (Table S1). This result suggests that, while an initial screen to obtain a clone with increased true-positive/false-positive ratio could reduce downstream applications, the demand to perform the initial screen may depend on the rate of recombination for a particular gene due to its size or to the fitness cost of gene disruption.
Table 7. Ratio of true positive to false positive colonies of TIGR4Δcps::NewSweetJanus and D39SΔcps::NewSweetJanus transformed with genomic DNA of different serotypes. NSJ refers to NewSweetJanus. Selection occurred on 800 µg/mL streptomycin (Strep), 10% sucrose (Suc), or 7.5–15 mM chlorinated-phenylalanine (Chl-Phe).

| Strain               | gDNA     | Selection  | Ratio |
|----------------------|----------|------------|-------|
| TIGR4Δcps::NSJ       | TIGR4 (4)| Strep, Suc | 0.08  |
| TIGR4Δcps::NSJ       | D39 (2)  | Strep, Suc | 1.33  |
| TIGR4Δcps::NSJ       | ABCA38 (22F) | Strep, Suc | 0     |
| TIGR4Δcps::NSJ       | CDC007 (6B) | Strep, Suc | 0.11  |
| TIGR4Δcps::NSJ       | ABCA31 (35B) | Strep, Suc | 0.07  |
| TIGR4Δcps::NSJ       | 45       | Strep, Suc | 0.10  |
| TIGR4Δcps::NSJ       | CDC001 (9V) | Strep, Suc | 0.04  |
| TIGR4Δcps::NSJ       | CDC004 (23F) | Strep, Suc | 0.09  |
| TIGR4Δcps::NSJ       | DAW4 (11) | Strep, Suc | 0.35  |
| TIGR4Δcps::NSJ       | ABCA61 (3) | Strep, Suc | 0     |
| TIGR4Δcps::NSJ       | CDC030 (12E) | Strep, Suc | 0     |
| TIGR4Δcps::NSJ       | CDC048 (18C) | Strep, Suc | 0.19  |
| TIGR4Δcps::NSJ       | CDC009 (15C) | Strep, Suc | 0.19  |
| D39SΔcps::NSJ        | TIGR4 (4) | Strep, Suc | 0.02  |
| D39SΔcps::NSJ        | D39 (2)  | Strep, Suc | 1.14  |
| D39SΔcps::NSJ        | ABCA38 (22F) | Strep, Suc | 0.02  |
| D39SΔcps::NSJ        | CDC007 (6B) | Strep, Suc | 0.06  |
| D39SΔcps::NSJ        | ABCA31 (35B) | Strep, Suc | 0.36  |
| D39SΔcps::NSJ        | 45       | Strep, Suc | 0     |
| D39SΔcps::NSJ        | CDC001 (9V) | Strep, Suc | 0.04  |
| D39SΔcps::NSJ        | CDC004 (23F) | Strep, Suc | 0.07  |
| D39SΔcps::NSJ        | DAW4 (11) | Strep, Suc | 0.20  |
| D39SΔcps::NSJ        | ABCA61 (3) | Strep, Suc | 0.03  |
| D39SΔcps::NSJ        | CDC030 (12E) | Strep, Suc | 0     |
| D39SΔcps::NSJ        | CDC048 (18C) | Strep, Suc | 0.05  |
| D39SΔcps::NSJ        | CDC009 (15C) | Strep, Suc | 0.09  |

3.3. Generation of Novel Markerless Cassettes

With the potential for reversion, the pneumococcus can exhibit high levels of false-positive colonies upon transformation (Figures 1 and 2). It is possible that other selection markers may work more effectively than streptomycin and sucrose. A potential alternative selection marker is chlorinated phenylalanine. In streptococci and lactococci, phenylalanyl-tRNA synthetase, encoded by *pheS*, specifically catalyzes attachment of phenylalanine to its cognate tRNA. A point mutation in *pheS* (A315G) renders the synthetase more promiscuous, whereby it becomes capable of attaching a chlorinated analog of phenylalanine. Incorporation of the chlorinated phenylalanine into proteins becomes deleterious and cells with this mutation are unable to grow [20,23]. This selection agent potentially could be used in conjunction with the Janus or Sweet Janus cassette in *S. pneumoniae*, providing a new dual selection marker, chlorinated phenylalanine and streptomycin, or a triple selection marker, chlorinated phenylalanine, streptomycin, and sucrose. Moreover, other combinations of selection markers are possible, including dual selection agents, chlorinated phenylalanine and sucrose, or single-selection agent chlorinated phenylalanine. These latter constructs would have the benefit of not requiring engineered resistance in the background strain since pneumococcus naturally does not integrate chlorinated phenylalanine and, therefore, growth on chlorinated phenylalanine is not inhibited. This unlocks a new set of applications for mutated strains that completely lack any non-native resistances. To test the efficacy of these potential new selection markers, we generated cassettes for deletion of capsule using the different combination of selection markers (Figure 4).
**Figure 4.** Schematic of novel markerless cassettes generated for allelic replacement of capsule. Each cassette was spliced between the genes flanking the capsule loci, *dexB* (tan) and *aliA* (yellow). The cassettes are comprised of genes that confer sucrose sensitivity (*sacB*; blue), kanamycin resistance (*kan*; purple), streptomycin sensitivity (*rpsL*; red), and chlorinated phenylalanine sensitivity (*pheS* A315G; green). The light gray box represents the promoter from Sweet Janus and the dark gray box represents ribosome-binding site. The light-tan box represents the sequence downstream of *dexB* and the light-yellow box represents the sequence upstream of *aliA* from D39. The direction of the arrow indicates the gene orientation.

To confirm these new cassettes function in the pneumococcus, we transformed TIGR4/TIGR4S and D39/D39S with each of these cassettes, which replace the capsule loci through homologous recombination with *dexB* and *aliA*. We isolated colonies that were unencapsulated and had no resistance to the counter-selection agents (Table 5). We then transformed each of the new strains with D39 genomic DNA and screened with the appropriate counter-selection agents. For all strains that contained the mutated *pheS*, we selected transformants on three different concentrations (7.5, 10, and 15 mM) of chlorinated phenylalanine to identify the concentration with the highest stringency [20,23]. We were able to obtain positive recombination of capsule for all strains except for TIGR4Acps::Phun (Figure 5). Here, 7.5–10 mM chlorinated phenylalanine for TIGR4 and 15 mM chlorinated phenylalanine for D39 yielded the best true-positive to false-positive ratios overall (Table 6). While using chlorinated phenylalanine alone (Phun) as a counter-selection agent is feasible, without a second agent, the frequency of false-positive is much higher than that with two or more counter-selection agents (Figure 5), similar to *sacB* or *rpsL* alone [11].

*phaS* was introduced upstream of the Janus cassette, replacing the *sacB* of Sweet Janus, and was termed Phun Janus (Figure S1D). To ensure proper expression, the promoter incorporated into Sweet Janus was duplicated directly upstream of *phaS*. For triple chlorinated phenylalanine, streptomycin, and sucrose counter-selection, a mutated *phaS* was introduced upstream of the Sweet Janus cassette through splicing of Sweet Janus and Phun Janus and was termed PhunSweet Janus (Figure S1F). To generate cassettes that did not rely on conferring the background strain with resistance, we constructed the PhunSweet cassette, which was comprised of a mutated *phaS* followed by *sacB* upstream of kanamycin resistance (Figure S1F), and the Phun cassette, which included the mutated *phaS* gene followed by kanamycin resistance (Figure S1G).

---

**Table 5.** Impacts of counter-selection agents on allelic replacement with *dexB* and *aliA* from D39. For dual chlorinated phenylalanine and streptomycin, we selected transformants on three different concentrations (7.5, 10, and 15 mM) of chlorinated phenylalanine to identify the concentration with the highest stringency [20,23]. We were able to obtain positive recombination of capsule for all strains except for TIGR4Acps::Phun (Figure 5). Here, 7.5–10 mM chlorinated phenylalanine for TIGR4 and 15 mM chlorinated phenylalanine for D39 yielded the best true-positive to false-positive ratios overall (Table 6). While using chlorinated phenylalanine alone (Phun) as a counter-selection agent is feasible, without a second agent, the frequency of false-positive is much higher than that with two or more counter-selection agents (Figure 5), similar to *sacB* or *rpsL* alone [11].
The development of Janus, Sweet Janus, and other genome editing methods, such as MuGENT, phenylalanine, streptomycin, and sucrose (PhunSweet Janus). Similar to Sweet Janus, these cassettes phenylalanine sensitivity in conjunction with those markers found in Sweet Janus. These cassettes previously as an alternative to alterations to HexA or RecA [7].

In the second step, the mutants from the first step are transformed with an alternate allele that replaces the cassette through homologous recombination, and transformants are selected on counter-selection agents listed in Table 5, with the concentration of chlorinated phenylamine ranging from 7.5 mM to 15 mM. The number of true-positive colonies (red bars, number above column) and the number of false-positive colonies (black bars) were determined per mL of transformation. Dashed line represents upper limit of detection.

4. Discussion

Possessing molecular tools is invaluable to the investigation of bacterial pathogenesis. The development of Janus, Sweet Janus, and other genome editing methods, such as MuGENT, has aided in studying deletion and allelic replacement of genes in S. pneumoniae [7,11,24]. In this study, through screening of sixteen isolated clones, we determined that the efficacy of allelic replacement can vary according to bacterial clone in that the ratio of true-positive/false-positive colonies varied. It is likely that there is an intrinsic element(s) that is altered during cell culture or transformation that leads to variances in parallel isolated colonies. As previously described, the frequency of reversion to streptomycin resistance could be impacted by the rpsL allele in the chromosome copy, the presence of RecA, and the activity of HexA [7]. SpnYL001 and TIGR4S streptomycin resistant background strains had the same single point mutation K56T, as confirmed by sequencing. With a single point mutation, the activity of HexA should have limited impact on the reversion of rpsL in Sweet Janus [7]. It is possible that the variability observed in revertant colonies could rely on expression or modification of RecA or some other component of recombination, competency, or mismatch repair. The variability could also stem from mutation of sacB resulting in loss of sucrose sensitivity. The cause for inconsistency may change upon each transformation and depend on the strain background, warranting a thorough initial screen to identify clones with reduced frequency of reversion. A similar screen was suggested previously as an alternative to alterations to HexA or RecA [7].

One aspect of the Janus and Sweet Janus systems that should be considered is the reliance on introduction of streptomycin resistance into the strain background. In this study, we created novel cassettes that do not require alterations to the strain background (i.e., introduction of resistance) before deletion of the gene of interest and instead rely on altered enzymatic activity to deleteriously incorporate chlorinated phenylalanine into proteins. We have also created cassettes that utilize chlorinated phenylalanine sensitivity in conjunction with those markers found in Sweet Janus. These cassettes are based on the same principal of Janus and follow a two-step transformation procedure (Figure 6).

In the first step, transformation of S. pneumoniae with the cassette spliced with the flanking regions of the target gene disrupts the gene through homologous recombination and mutants are selected on kanamycin. In the second step, the mutants from the first step are transformed with an alternate allele that replaces the cassette through homologous recombination, and transformants are selected on the appropriate counter-selection agent: chlorinated phenylalanine (Phun), chlorinated phenylalanine and sucrose (PhunSweet); chlorinated phenylalanine and streptomycin (Phun Janus); and chlorinated phenylalanine, streptomycin, and sucrose (PhunSweet Janus). Similar to Sweet Janus, these cassettes

![Figure 5](https://example.com/figure5.png)

**Figure 5.** Novel cassettes are effective for allelic replacement of capsule. Cassettes (below column) replaced the capsule loci in (a) TIGR4/TIGR4S and (b) D39/D39S. The acapsular mutants were transformed with D39 genomic DNA and transformants were selected on counter-selection agents listed in Table 5, with the concentration of chlorinated phenylamine ranging from 7.5 mM to 15 mM. The number of true-positive colonies (red bars, number above column) and the number of false-positive colonies (black bars) were determined per mL of transformation. Dashed line represents upper limit of detection.
demonstrate variable rates of transformation efficacy that may hinge upon selection of the initial clone. Although these cassettes do not overcome the pitfall of potential reversion, they offer new possibilities for molecular manipulation of \textit{S. pneumoniae} and provide a multitude of counter-selection agents for use depending on the restrictions of the experiment.

![Diagram](https://example.com/diagram.png)

**Figure 6.** Mutation of \textit{S. pneumoniae} using novel cassettes occurs in a two-step transformation procedure. The schematic indicates the selection agents and the agents that inhibit growth of transformants for each transformation step. The selection agents are represented by a colored shape: blue square for sucrose; purple triangle for kanamycin; green circle for chlorinated phenylalanine; red diamond for streptomycin.

5. Conclusions

In this study, we have identified a potential drawback when utilizing Sweet Janus for large scale allelic replacement in \textit{S. pneumoniae}. We determined that the level of false-positive colonies was dependent on the initial selected clone. Thus, a pre-screening measure may be warranted to identify a clone with a low number of false-positive colonies in order to streamline numerous allelic replacements in the same background. We have also generated several new constructs for allelic replacement that provide alternative selection agents to those in Sweet Janus. Two of the constructs (PhunSweet and Phun) do not rely on conferring resistance to the background strain, providing a means of generating a true markerless genetic replacement. These new constructs provide a new method for genetic manipulation of \textit{S. pneumoniae}, expanding experimental applications.

**Supplementary Materials:** The following are available online at [http://www.mdpi.com/2073-4425/11/9/965/s1](http://www.mdpi.com/2073-4425/11/9/965/s1), Figure S1: Schematic of PCR primers and template used to generate novel markerless cassettes for allelic replacement of capsule.; Figure S2: TIGR4 does not share homology with D39 for upstream sequence of \textit{aliA}; Table S1: Number and ratio of true positive to false positive colonies of allelic replacement of \textit{spxB}.

**Author Contributions:** Conceptualization, H.E. and J.W.R.; methodology, H.E. and J.W.R.; software, H.E. and J.W.R.; validation, H.E.; formal analysis, H.E.; investigation, H.E.; resources, J.W.R.; data curation, H.E.; writing—original draft preparation, H.E.; writing—review and editing, H.E. and J.W.R.; visualization, H.E. and J.W.R.; supervision, J.W.R.; project administration, J.W.R.; funding acquisition, J.W.R. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was supported by NIH (National Institutes of Health) grants 5U01AI124302 and 5R01AI110618-0 to JWR and ALSAC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Acknowledgments:** SpnYL001 was generously provided by Yuan Li from the Harvard School of Public Health. CDC isolates were generously provided by the CDC Active Bacterial Core Surveillance System.

**Conflicts of Interest:** The authors declare no conflict of interest.
References

1. Henriques-Normark, B.; Tuomanen, E.I. The pneumococcus: Epidemiology, microbiology, and pathogenesis. *Cold Spring Harb. Perspect. Med.* 2013. [CrossRef]

2. Wyres, K.L.; Lambertz, L.M.; Croucher, N.J.; McGee, L.; von Gottberg, A.; Linares, J.; Jacobs, M.R.; Kristinsson, K.G.; Beall, B.W.; Klugman, K.P.; et al. Pneumococcal capsular switching: A historical perspective. *J. Infect. Dis.* 2013, 207, 439–449. [CrossRef]

3. Salvadori, G.; Junge, R.; Morrison, D.A.; Petersen, F.C. Competence for genetic transformation in encapsulated strains of *Streptococcus pneumoniae*. *BMC Microbiol.* 2019, 19, 27–35. [CrossRef]

4. Daniels, C.C.; Rogers, P.D.; Shelton, C.M. A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein Antigens. *J. Pediatr. Pharmacol. Ther.* 2016, 21, 1–8. [CrossRef]

5. Kim, G.L.; Seon, S.H.; Rhee, D.K. Pneumonia and *Streptococcus pneumoniae* vaccine. *Arch. Pharm. Res.* 2017, 40, 885–893. [CrossRef]

6. Ramirez, M.; Morrison, D.A.; Tomasz, A. Ubiquitous distribution of the competence related genes comA and comC among isolates of *Streptococcus pneumoniae*. *Microb. Drug Resist.* 1997, 3, 39–52. [CrossRef]

7. Sung, C.K.; Li, H.; Claverys, J.P.; Morrison, D.A. An rpsL cassette, janus, for gene replacement through negative selection in *Streptococcus pneumoniae*. *Appl. Environ. Microbiol.* 2001, 67, 5190–5196. [CrossRef]

8. Trzcinski, K.; Thompson, C.M.; Lipsitch, M. Construction of otherwise isogenic serotype 6B, 7F, 14, and 19F capsular variants of *Streptococcus pneumoniae* strain TIGR4. *Appl. Environ. Microbiol.* 2003, 69, 7364–7370. [CrossRef]

9. Bartual, S.G.; Straume, D.; Stamsas, G.A.; Munoz, I.G.; Alfonso, C.; Martinez-Ripoll, M.; Havarstein, L.S.; Hermoso, J.A. Structural basis of PcsB-mediated cell separation in *Streptococcus pneumoniae*. *Nat. Commun.* 2014, 5, 1–12. [CrossRef]

10. Matthias, K.A.; Roche, A.M.; Standish, A.J.; Shchepetov, M.; Weiser, J.N. Neutrophil-toxin interactions promote antigen delivery and mucosal clearance of *Streptococcus pneumoniae*. *J. Immunol.* 2008, 180, 6246–6254. [CrossRef]

11. Li, Y.; Thompson, C.M.; Lipsitch, M. A modified Janus cassette (Sweet Janus) to improve allelic replacement efficiency by high-stringency negative selection in *Streptococcus pneumoniae*. *PLoS ONE* 2014, 9, e100510. [CrossRef]

12. Echlin, H.; Frank, M.W.; Iverson, A.; Chang, T.C.; Johnson, M.D.; Rock, C.O.; Rosch, J.W. Pyruvate Oxidase as a Critical Link between Metabolism and Capsule Biosynthesis in *Streptococcus pneumoniae*. *PLoS Pathog.* 2016, 12, e1005951. [CrossRef]

13. Wang, C.Y.; Medlin, J.S.; Nguyen, D.R.; Disbennett, W.M.; Dawid, S. Molecular Determinants of Substrate Selectivity of a Pneumococcal Rgg-Regulated Peptidase-Containing ABC Transporter. *mBio* 2020, 11. [CrossRef]

14. Tothpal, A.; Desobry, K.; Yoshi, S.S.; Wyllie, A.L.; Weinberger, D.M. Variation of growth characteristics of *Streptococcus pneumoniae* by PCR and transformation. *Microb. Drug Resist.* 2019, 39, 508–517. [CrossRef]

15. Vimberg, V.; Zieglerova, L.; Buriankova, K.; Branny, P.; Balikova Novotna, G. VanZ Reduces the Binding of Lipoglycopeptide Antibiotics to *Staphylococcus aureus* and *Streptococcus pneumoniae* Cells. *Front. Microbiol.* 2020, 11, 566. [CrossRef]

16. Lacks, S.; Hotchkiss, R.D. A study of the genetic material determining enzyme in the pneumococcus. *Biochim. Biophys. Acta* 1960, 39, 508–517. [CrossRef]

17. Horton, R.M.; Cai, Z.L.; Ho, S.N.; Pease, L.R. Gene splicing by overlap extension: Tailor-made genes using the polymerase chain reaction. *Biotechniques* 1990, 8, 528–535. [CrossRef]

18. Pozzi, G.; Masala, L.; Ianneli, F.; Manganelli, R.; Havarstein, L.S.; Piccoli, L.; Simon, D.; Morrison, D.A. Competence for genetic transformation in encapsulated strains of *Streptococcus pneumoniae*: Two allelic variants of the peptide pheromone. *J. Bacteriol.* 1996, 178, 6087–6090. [CrossRef]

19. Martin-Galiano, A.J.; de la Campa, A.G. High-efficiency generation of antibiotic-resistant strains of *Streptococcus pneumoniae* by PCR and transformation. *Antimicrob. Agents Chemother.* 2003, 47, 1257–1261. [CrossRef]

20. Gurung, I.; Berry, J.L.; Hall, A.M.J.; Pelicic, V. Cloning-independent markerless gene editing in *Streptococcus sanguinis*: Novel insights in type IV pilus biology. *Nucleic Acids Res.* 2017, 45, e40. [CrossRef]
21. Salles, C.; Creancier, L.; Claverys, J.P.; Mejean, V. The high level streptomycin resistance gene from *Streptococcus pneumoniae* is a homologue of the ribosomal protein S12 gene from *Escherichia coli*. *Nucleic Acids Res.* 1992, 20, 6103. [CrossRef] [PubMed]

22. Khetrapal, V.; Mehershahi, K.; Rafee, S.; Chen, S.; Lim, C.L.; Chen, S.L. A set of powerful negative selection systems for unmodified Enterobacteriaceae. *Nucleic Acids Res.* 2015, 43, e83. [CrossRef] [PubMed]

23. Xin, Y.; Guo, T.; Mu, Y.; Kong, J. Development of a counterselectable seamless mutagenesis system in lactic acid bacteria. *Microb. Cell Fact.* 2017, 16, 1–13. [CrossRef]

24. Dalia, A.B.; McDonough, E.; Camilli, A. Multiplex genome editing by natural transformation. *Proc. Natl. Acad. Sci. USA* 2014, 111, 8937–8942. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).